EP Patent

EP4272839A3 — Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Assigned to Glenmark Specialty SA · Expires 2024-01-03 · 2y expired

What this patent protects

The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.

USPTO Abstract

The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.

Drugs covered by this patent

Patent Metadata

Patent number
EP4272839A3
Jurisdiction
EP
Classification
—
Expires
2024-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Glenmark Specialty SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.